The timeline: when does each stage happen?
The average age of menopause in the United States is 51, but the range is wide (45 to 55 for most women). Early menopause (before 45) and premature ovarian insufficiency (before 40) are distinct conditions that warrant earlier evaluation and often more aggressive HRT consideration.
Stages at a glance
| Timing | Defining feature | |
|---|---|---|
| Perimenopause | Typically ages 40 to 51; can start late 30s | Irregular cycles; hormone fluctuation; symptoms begin |
| Menopause | Average age 51 (US) | 12 consecutive months without a period |
| Postmenopause | After menopause, permanent | Stable low estrogen; bone and CV changes ongoing |
Perimenopause symptoms
Perimenopause symptoms arise because estrogen and progesterone fluctuate unpredictably, surging and dropping rather than declining steadily. This is why the experience often feels chaotic and inconsistent.
Most common perimenopause symptoms
- Irregular periods: shorter, longer, heavier, lighter, or skipped cycles
- Hot flashes and night sweats (vasomotor symptoms)
- Sleep disruption, often related to night sweats but also independent
- Mood changes: irritability, anxiety, low mood; sometimes meeting criteria for depression
- Cognitive changes: brain fog, word-finding difficulty, memory lapses
- Vaginal dryness or discomfort during intercourse
- Decreased libido
- Joint pain and muscle aches
- Weight gain, particularly in the abdominal area
- Headaches that can worsen in this period
Menopause and postmenopausal symptoms
Menopause and postmenopause are defined by permanently low estrogen. Vasomotor symptoms often peak in the early postmenopausal period and gradually ease for most women. Other effects tend to persist or worsen, including genitourinary syndrome of menopause (GSM), bone density loss, and increasing cardiovascular risk relative to premenopausal baseline.
Side-by-side comparison
| Perimenopause | Menopause / Postmenopause | |
|---|---|---|
| Menstrual cycles | Irregular but present | Absent (12+ months) |
| Average duration | 4 to 8 years | Permanent |
| Hormone pattern | Fluctuating estrogen; progesterone drops first | Steadily low estrogen |
| FSH | Variably elevated | Consistently >25 IU/L |
| Pregnancy risk | Yes; contraception still needed | No |
| Hot flash timing | Can be prominent | Often peak early postmenopause |
| GSM | Begins in late perimenopause | Worsens over time without treatment |
| Bone loss | Accelerates in late peri | Continues postmeno |
Treatment options
Hormone Replacement Therapy (HRT)
The most evidence-backed treatment for moderate-to-severe vasomotor symptoms and for bone density preservation. The NAMS 2022 position statement confirms that for healthy women under 60 (or within 10 years of menopause onset), the benefits of HRT outweigh the risks for most women. [1][2]
Formulations include estradiol (patches, gels, creams, sprays, pills), micronized progesterone (recommended over synthetic progestins for women with a uterus), and vaginal estradiol for genitourinary symptoms (minimal systemic absorption).
The 2002 Women's Health Initiative caused widespread concern about HRT safety; subsequent re-analyses substantially revised that picture. The 'timing hypothesis' establishes that HRT initiated within 10 years of menopause onset carries a different risk profile than initiation in older postmenopausal women. Your Genesis provider discusses your individual risk factors in this context. [1]
Compounded BHRT
Compounded bioidentical preparations are available and used at Genesis with full disclosure of FDA approval status. See the dedicated HRT vs BHRT comparison for the trade-offs.
Non-hormonal options
- SSRIs and SNRIs: paroxetine (FDA-approved for vasomotor symptoms), venlafaxine, and others
- Gabapentin: off-label, moderate evidence for hot flash reduction
- Fezolinetant (Veoza): FDA-approved non-hormonal for vasomotor symptoms (2023)
- Cognitive behavioral therapy: evidence-based for hot flash burden, sleep, and mood